ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0514

Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen

Christine Wang1, Rebecca Sadun2, Wenru Zhou3, Kristen Miller3, Claire Palmer3, Stacy P Ardoin4, Christine Bacha5, Emily Hause6, Joyce Hui-Yuen7, Nicole Ling8, Maria Pereira9, Meredith Riebschleger10, Kelly Rouster-Stevens11, Aliese Sarkissian12, Julia Shalen13, William Soulsby14, Marinka Twilt15, Eveline Wu16, Laura Lewandowski17, Scott Wenderfer18 and Jennifer Cooper19, 1Children's Hospital of Colorado/University of Colorado, Denver, CO, 2Duke University, Durham, NC, 3University of Colorado School of Medicine, Aurora, CO, 4Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 5Nationwide Children's Hospital, Columbus, OH, 6University of Minnesota, Minneapolis, MN, 7Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, 8UCSF, San Francisco, CA, 9Baylor College of Medicine, Houston, TX, 10University of Michigan, Ann Arbor, MI, 11Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children’s Healthcare of Atlanta, Atlanta, GA, 12University of North Carolina at Chapel Hill, Chapel Hill, NC, 13Johns Hopkins University, Baltimore, MD, 14University of California, San Francisco, San Francisco, CA, 15Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 16University of North Carolina, Chapel Hill, NC, 17NIAMS, NIH, Bethesda, MD, 18British Columbia Children's Hospital, Vancouver, BC, Canada, 19Children's Hospital of Colorado/University of Colorado, Aurora, CO

Meeting: ACR Convergence 2022

Keywords: Cohort Study, Lupus nephritis, Pediatric rheumatology, Renal, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Abstracts: Pediatric Rheumatology – Clinical I: Connective Tissue Disease

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: There have been no published studies comparing renal outcomes of youth with proliferative lupus nephritis (LN) treated with the lower-dose EuroLupus (EL) cyclophosphamide (CYC) regimen vs. the NIH regimen. We aimed to evaluate the association between the CYC dosing regimen and renal response at 12 months.

Methods: A multisite retrospective cohort study was conducted at 11 North American pediatric centers using electronic medical record data. Patients 6 to 22 years of age with active proliferative LN treated with either the EL or NIH regimen from 7/1/2014 to 6/30/2021 were included. Data were obtained through 12 months after baseline (defined as start of most recent CYC course). The primary outcome was the proportion of patients with complete (CRR) or partial renal response (PRR) at 12 months. The secondary outcome was the proportion of patients with CRR at 12 months. CRR was defined as normal estimated glomerular filtration rate (eGFR > 90 mL/min/1.72 m2) and urine protein-to-creatinine ratio (UPCR) < 0.2. PRR was defined as ≥ 50% improvement in eGFR and UPCR if abnormal at baseline and UPCR ≤ 1. Urine sediment was excluded from response definitions due to inability to exclude concurrent menses (hematuria), infection (pyuria) and missing values (casts). Baseline characteristics were compared by CYC regimen using two-sample independent t-tests or Wilcoxon rank sum tests for continuous variables and Chi-square tests or Fisher’s exact tests for categorical variables. A generalized linear model with logit link was fit to evaluate the association of CYC regimen (EL vs. NIH) with renal response. We used a propensity score model and inverse probability weighting to balance clinically important baseline covariates. We adjusted for confounders and precision variables that remained unbalanced in the synthetic dataset.

Results: One hundred and sixty-two patients (97 NIH, 65 EL) were included. Baseline characteristics were similar between groups. EL patients were on average older at the start of current CYC therapy, had longer SLE disease duration and were more likely to have relapsed or refractory LN compared to the NIH group (Table 1). Intravenous (IV) steroid use and mean oral prednisone doses were not significantly different at baseline, 3, 6, and 12 months. The mean eGFR and UPCR improved over the course of study, though the mean UPCR remained >1 (Figure 1). At 12 months, 42% of EL and 53% of NIH treated patients achieved CRR or PRR (p = 0.25), and 19% of EL and 40% of NIH treated patients achieved CRR (p = 0.01). After multivariable adjustment (Table 2), at 12 months there was no significant association between the CYC dosing regimen used and achieving PRR or CRR (OR 0.79, 95% CI 0.34, 1.87) and CRR only (OR 0.80, 95% CI 0.30, 2.11).

Conclusion: Our study found no significant association between CYC regimen (EL vs. NIH) and renal response at 12-months, after multivariable adjustment. However, the study was retrospective and was not powered for non-inferiority. Nevertheless, our data suggest that EL dosing may be a reasonable alternative for treatment of youth with proliferative LN, especially given the potential benefits of lower cumulative CYC exposure. Future prospective studies and longer-term outcome data are needed.

Supporting image 1

Table 1: Baseline Characteristics of the Cohort

Supporting image 2

Table 2. Adjusted Renal Response Outcomes at 12 Months

Supporting image 3

Figure 1. Change in Estimated Glomerular Filtration Rate (eGFR) and Urine Protein-to-Creatinine Ratio (UPCR) Over Time by Dosing Regimen. (A) Mean eGFR (mL/min/per 1.73 m2) over time with 95% confidence interval bands. (B) Mean UPCR (mg protein/mg creatinine) over time, with 95% confidence interval bands.


Disclosures: C. Wang, None; R. Sadun, None; W. Zhou, None; K. Miller, None; C. Palmer, None; S. Ardoin, None; C. Bacha, None; E. Hause, None; J. Hui-Yuen, None; N. Ling, None; M. Pereira, None; M. Riebschleger, None; K. Rouster-Stevens, Accordant; A. Sarkissian, None; J. Shalen, None; W. Soulsby, None; M. Twilt, None; E. Wu, Pharming Healthcare, Inc, AstraZeneca, Bristol-Myers Squibb(BMS), Janssen; L. Lewandowski, None; S. Wenderfer, Bristol-Myers Squibb(BMS), Alnylam; J. Cooper, None.

To cite this abstract in AMA style:

Wang C, Sadun R, Zhou W, Miller K, Palmer C, Ardoin S, Bacha C, Hause E, Hui-Yuen J, Ling N, Pereira M, Riebschleger M, Rouster-Stevens K, Sarkissian A, Shalen J, Soulsby W, Twilt M, Wu E, Lewandowski L, Wenderfer S, Cooper J. Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/renal-response-outcomes-of-north-american-youth-with-proliferative-lupus-nephritis-treated-with-the-eurolupus-versus-nih-cyclophosphamide-dosing-regimen/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/renal-response-outcomes-of-north-american-youth-with-proliferative-lupus-nephritis-treated-with-the-eurolupus-versus-nih-cyclophosphamide-dosing-regimen/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology